Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers.  Biomea Fusion's lead investigational compound, BMF-219, is a covalent menin inhibitor.  The company also develops BMF-500, a covalent FLT3 inhibitor.

Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

COM:BIOMEAFUSION

Biomea Fusion

Last Close

6.38

22/11 21:00

Market Cap

145.32M

Beta: -

Volume Today

490.54K

Avg: -

Analysis Not Available